Cancer

April 28, 2025

Three Vanderbilt-affiliated cellular therapy programs receive reaccreditation

The Vanderbilt and VA Tennessee Valley Healthcare System programs received notification after on-site inspections in October 2024. The accreditation is effective for three years.

The cellular therapy programs at Vanderbilt-Ingram Cancer Center, Monroe Carell Jr. Children’s Hospital at Vanderbilt, and the VA Tennessee Valley Healthcare System have received reaccreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).

Founded in 1995, FACT establishes standards for high quality medical and laboratory practice in cellular therapies. FACT is a nonprofit corporation co-founded by the International Society for Cell and Gene Therapy and the American Society for Transplantation and Cellular Therapy for the purposes of voluntary inspection and accreditation in the field of cellular therapy.

“FACT is an internationally recognized accrediting body for hospitals that offer stem cell transplant and cellular therapy, and recognition by FACT indicates that the accredited institution has met the most rigorous standard in every aspect of cellular therapy,” said Adetola Kassim, MD, professor of Medicine and director of the Vanderbilt Stem Cell Transplant and Cellular Therapy Program. “This covers the entire spectrum of stem cell therapy from clinical care to donor management, cell collection, processing, storage, transplant, administration and cell release.”

The Vanderbilt and VA Tennessee Valley Healthcare System programs received accreditation notification on April 14 after on-site inspections in October 2024. The accreditation is effective for three years.

“Congratulations to the entire Vanderbilt University Medical Center and VA Tennessee Valley Healthcare System team on achieving FACT accreditation and providing quality care for the people we serve,” Kassim said.